Targeted drug shows promise for Hard-to-Treat cancers with genetic marker
NCT ID NCT04520269
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 25 times
Summary
This study tests a drug called pacritinib in people with advanced solid tumors, including breast cancer, that have a specific genetic change called 1q21.3 amplification. The goal is to see if the drug can shrink tumors or slow their growth. About 74 participants will receive the drug, and researchers will monitor safety and how well it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National University Hospital
Singapore, Singapore
Conditions
Explore the condition pages connected to this study.